David Banach
Overview
Explore the profile of David Banach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Z, Zhang S, Zhang J, Avery L, Banach D, Zhao H, et al.
Adv Sci (Weinh)
. 2024 Apr;
11(23):e2310066.
PMID: 38634211
Simple, sensitive, and accurate molecular diagnostics are critical for preventing rapid spread of infection and initiating early treatment of diseases. However, current molecular detection methods typically rely on extensive nucleic...
2.
Zhang J, Li Z, Guo C, Guan X, Avery L, Banach D, et al.
Angew Chem Int Ed Engl
. 2024 Mar;
63(20):e202403123.
PMID: 38516796
The CRISPR-Cas12a system has emerged as a powerful tool for next-generation nucleic acid-based molecular diagnostics. However, it has long been believed to be effective only on DNA targets. Here, we...
3.
Li Z, Uno N, Ding X, Avery L, Banach D, Liu C
ACS Nano
. 2023 Feb;
17(4):3966-3975.
PMID: 36762838
HIV molecular detection plays a significant role in early diagnosis and antiretroviral therapy for HIV patients. CRISPR technology has recently emerged as a powerful tool for highly sensitive and specific...
4.
Goenka R, Xu Z, Samayoa J, Banach D, Beam C, Bose S, et al.
J Immunol
. 2021 Jan;
206(5):1102-1113.
PMID: 33495237
CTLA4-Ig/abatacept dampens activation of naive T cells by blocking costimulation via CD28. It is an approved drug for rheumatoid arthritis but failed to deliver efficacy in a number of other...
5.
Hoemann M, Wilson N, Argiriadi M, Banach D, Burchat A, Calderwood D, et al.
Bioorg Med Chem Lett
. 2016 Oct;
26(22):5562-5567.
PMID: 27789138
A series of furano[3,2-d]pyrimidine Syk inhibitors were synthesized and optimized for their enzyme potency and selectivity versus other kinases. In addition, ADME properties were assessed and compounds were prepared with...
6.
Argiriadi M, Banach D, Radziejewska E, Marchie S, DiMauro J, Dinges J, et al.
Bioorg Med Chem Lett
. 2016 Mar;
26(9):2293-6.
PMID: 27013389
S1P Lyase (SPL) has been described as a drug target in the treatment of autoimmune diseases. It plays an important role in maintaining intracellular levels of S1P thereby affecting T...
7.
Barria M, Garrido J, Stein C, Scher E, Ge Y, Engel S, et al.
J Infect Dis
. 2012 Oct;
207(1):115-24.
PMID: 23087433
Background: Influenza virus infection is a major public health burden worldwide. Available vaccines include the inactivated intramuscular trivalent vaccine and, more recently, an intranasal live attenuated influenza vaccine (LAIV). The...
8.
Argiriadi M, Goedken E, Banach D, Borhani D, Burchat A, Dixon R, et al.
BMC Struct Biol
. 2012 Sep;
12:22.
PMID: 22995073
Background: Structure-based drug design (SBDD) can accelerate inhibitor lead design and optimization, and efficient methods including protein purification, characterization, crystallization, and high-resolution diffraction are all needed for rapid, iterative structure...
9.
Pica N, Hai R, Krammer F, Wang T, Maamary J, Eggink D, et al.
Proc Natl Acad Sci U S A
. 2012 Feb;
109(7):2573-8.
PMID: 22308500
After the emergence of pandemic influenza viruses in 1957, 1968, and 2009, existing seasonal viruses were observed to be replaced in the human population by the novel pandemic strains. We...
10.
Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E
Am J Public Health
. 2011 Sep;
101(11):2151-5.
PMID: 21940910
Objectives: Between April and September of 2009 we evaluated the accuracy of the OraQuick HCV rapid antibody test and assessed its feasibility for use by community-based organizations (CBOs) serving populations...